Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).

Molecular lesion data in LR-MDS prognostic models reduce the significance of traditional parameters like bone marrow blast percentage. Molecular data altered risk stratification for 30% of patients, ...

Patients with MDS report more symptoms than physicians, indicating a communication gap in symptom assessment. Allogeneic hematopoietic stem cell transplantation is the only cure but is limited to ...

Dr Komrokji explains how the IPSS-M improves prognostic precision in MDS but cautions that upstaging alone should not ...

R289, a dual inhibitor of IRAK1 and IRAK4, targets inflammatory signaling in LR-MDS, potentially improving patient outcomes. The phase 1B study of R289 shows 36% of patients achieving transfusion ...

All trial regimens evaluated were safe, but the five-day regimen offered the best balance of safety and efficacy ORLANDO, DECEMBER 7, 2025 – Patients with lower-risk myelodysplastic syndromes (MDS) ...

Rytelo (imetelstat) is a medicine used to treat myelodysplastic syndromes (MDS). MDS is a rare group of disorders that affect your blood cells. Most people who get MDS are 65 years of age or older, ...

Low-dose Revlimid delayed transfusion dependency and improved treatment response rates in non-transfusion dependent MDS patients. Revlimid reduced the risk of transfusion dependency by 69.8% compared ...